{"task_id": "230f636f34577260", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 17/464)", "text": "ger Science\u00feBusiness Media, LLC 2006, 2007, 2011\n1\n\n--- Page 23 ---\nLONG TERM MANAGEMENT\nEDUCATION\nsmoking cessation (see p. 418).\nAsthma action plan. Puffer technique education\nand review\nENVIRONMENTAL CONTROL\navoidance of out\ndoor/indoor\nallergens,\nirritants,\nand\ninfections;\nhome environment cleanliness (e.g. steam cleaning)\nVACCINATIONS\ninfluenza vaccine annually and\npneumococcal vaccine booster at 5 years\nFIRST LINE\nshort acting b2 agonist (salbutamol\n2 puffs PRN). Proceed to second line if using more\nthan 2\u0003/week or 1\u0003/day for exercise induced symp\ntoms, symptoms >2\u0003/week, any nocturnal symp\ntoms, activity limitation or PEF <80%\nSECOND LINE\ninhaled corticosteroids plus short\nacting b2 agonist PRN\nTHIRD LINE\ninhaled corticosteroid plus long acting\nb2 agonist (note that long acting b2 agonist should\nnever be used alone in asthma), leukotriene receptor\nantagonist (most effective in asthma complicated with\nsinus disease and exercise induced asthma)\nFOURTH LINE\nanti IgE therapy (omalizumab) for\nrefractory allergic asthma, administered subcuta\nneously q2 4weeks, dosed by IgE level and body\nweight, for add on therapy or inadequately controlled\nmoderate to severe allergic asthma despite use of\nhigh doses of inhaled corticosteroid therapy\nNEJM 2009 360:10\nTREATMENT ISSUES\nCOMMON INHALED MEDICATIONS\n\u0002\nSHORT-ACTING b AGONISTS\nsalbutamol metered\ndose inhaler (MDI) 100 mg 1 2 puffs PRN or\n2.5 mg NEB PRN, fenoterol MDI 100 mg 1 2 puffs\nPRN, terbutaline 500 mg INH PRN\n\u0002\nSHORT-ACTING ANTICHOLINERGICS\nipratropium MDI\n20 mg 2 puffs QID or 500 mg NEB QID\n\u0002\nLONG-ACTING b AGONISTS\nformoterol 6 24 mg INH\nBID, salmeterol diskus 50 mg i puff BID\n\u0002\nLONG-ACTING ANTICHOLINERGICS\ntiotropium 18 mg\nINH daily\n\u0002\nINHALED CORTICOSTEROIDS\nbeclomethasone 50 400\nmg INH BID, budesonide turbuhaler 200 400 mg\nINH BID or 0.5 1 mg NEB BID, fluticasone\n125 250 mg INH BID, ciclesonide MDI 100 400\nmg INH daily (only indicated for asthma at this\ntime, not COPD)\nRelated Topics\nChronic Obstructive Pulmonary Disease (p. 3)\nPulmonary Function Tests (p. 21)\nADMISSION CRITERIA\nFEV1 (L)\nPEF (L/min)\nPaO2\nAction\nVery severe\n<90% with O2\nAdmit\nSevere\n<1.6 (<40%)\n<200 (<40%)\n<90%\nAdmit\nModerate\n1.6 2.1\n200 300\n>90%\nAdmit?\nMild\n>2.1 (>60%)\n>300 (>60%)\n>90%\nSend home\nDISCHARGE CRITERIA\nconsider discharging patient if peak flow >70% of usual (or predicted) value for at\nleast 1 h after bronchodilator\nOXYGEN DELIVERY DEVICES\nDevice\nFlow rates\nDelivered O2\nNasal cannula\n1 L/min\n21 24%\n2 L/min\n25 28%\n3 L/min\n29 32%\n4 L/min\n33 36%\n5 L/min\n37 40%\n6 L/min\n41 44%\nSimple oxygen face mask\n6 10 L/min\n35 60%\nFace mask with oxygen reservoir\n6 L/min\n60%\n(non rebreather mask)\n7 L/min\n70%\n8 L/min\n80%\n9 L/min\n90%\n10 15 L/min\n95+%\nVenturi mask\n4 8 L/min\n24 40%\n10 12 L/min\n40 50%\nNOTE: delivered O2 (FiO2) is approximate. Oxygen delivery can approach 100% with intubation and\nmechanical ventilation\n2\nAsthma Exacerbation", "text_length": 2897, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 17/464)", "type": "chunk", "chunk_index": 16, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.255136", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.255869", "status": "complete", "chunks_added": 2}